Eli Lilly shares are now positive for the year, up 10% since the start of January.

The mid-stage trial results announced by the pharmaceutical giant showed that patients taking orforglipron lost an average of 16 pounds.

Most Wall Street stocks were little changed and the dollar ticked up on Thursday as investors took some heart from trade ...